Article Text
PDF
Statistics from Altmetric.com
- antilipaemic agents (cardiovascular diseases)
- cholesterol
- diabetes mellitus (type 2)
- dyslipidaemias
- procetofen
- triglycerides
Q In patients with type 2 diabetes mellitus, what is the effect of long term fenofibrate therapy on coronary heart disease (CHD) events?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Geriatrics ★★★★★☆☆
METHODS
Design
randomised placebo-controlled trial (Fenofibrate Intervention and Event Lowering in Diabetes [FIELD]).
Allocation
concealed.*
Blinding
blinded (clinicians, patients, and outcome assessors).*
Follow up period
median 5 years.
Setting
63 centres in Australia, New Zealand, and Finland.
Patients
9795 patients 50–75 years of age (mean age 62 y, 63% men) who had a World Health Organization diagnosis of type 2 diabetes, total cholesterol concentration 3–6.5 mmol/l, and a total cholesterol/high density lipoprotein (HDL) cholesterol ratio ⩾4 or a triglyceride concentration of 1–5 mmol/l, with no clear indication for lipid modifying therapy. Exclusion criteria were renal impairment, chronic liver disease, symptomatic gallbladder disease, or occurrence of a cardiovascular disease (CVD) event within 3 months …
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Linked Articles
- Glossary